In human clinical studies summarized in the PMC review on pomegranate and cardiovascular protection, participants consumed about 50 mL of pomegranate juice per day (roughly one-fifth of a standard glass)
The SURMOUNT-5 head-to-head trial directly compared Zepbound to Wegovy, with results published in The New England Journal of Medicine: The addition of GIP receptor activation unlocks approximately 6% additional fat loss compared to GLP-1-only medications, while also helping preserve muscle mass better
Report persistent nausea or vomiting to your healthcare provider, as severe symptoms may require dose adjustment or additional management strategies
The body has a drive towards balance, especially at the cellular level
Some participants reported nausea and diarrhea as the most common side effects, but those were generally mild and easily managed
Weight Loss Results: Clinical Evidence From Trials Wegovy's pivotal trial, STEP 1, demonstrated that participants on the 2.4 mg weekly dose lost an average of 15% of their body weight over 68 weeks, with many individuals achieving 20% reduction or more
